We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
In My Kitchen is a platform that aims to bring together a network of professional and semi-professional chefs to sell their signature dishes and recipes online. The platform was founded in July 2020. In My Kitchen asserts that its business model holds precedence in a time where takeaways have grown in popularity in the UK because of COVID-19. It gives many chefs who have become unemployed or have fewer shifts for developing their creativity and skills whilst allowing them to earn through the gig-economy. The company has a network of more than 70 chefs across London, with backgrounds across a range of cuisines. With the investment received, the company will develop its team and company infrastructure.

Pitch Rated

31%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Fuudel seamlessly connects food operators to consumers using an on demand service. Their platform goes beyond ordering, providing cutting edge tools and services to help food businesses to thrive. Founder Dabier Miya previously had a highly successful enterprise software sales career and in 2004 began what was intended to be a one off investment in a restaurant venture which then led to a decade journey and half a dozen restaurants. 
days to go: Expired investment: £70,675
EMIXIT has built a B2B ecommerce platform wholesaling products from UK suppliers directly to trade buyers across Europe. Over 40 brands with 250+ products have already registered on the platform paying a fee. EMIXIT allows buyers to make up mixed pallets from different suppliers, in their local language, over labelled and delivered to the door – a “one-stop-shop”. Their service is aimed at buyers from small retail or foodservice chains to large multiple supermarkets and hotel/restaurant chains. www.emixit.eu.
days to go: Expired investment: £58,320
A grocery delivery service for customers to purchase goods from local stores via an app. Grocemania launched in August 2017 and has signed more than 20 local and independent stores and gained over 350 users. Income is generated from a flat delivery fee of £2.50, as well as a 10% Commission Fee from its partners. The company has generated more than £27,000 in online sales for local stores in the past 3 months.
days to go: Expired investment: £76,557
MenuLab helps food businesses track allergens in the food they serve to customers via a smartphone app. 
days to go: Expired investment: £1,989
Tribal Sports Nutrition is a real food active nutrition company.  They are focused on bring the baobab fruit from Africa to everyday lives in the form of a fruit smoothie.  The investment will enable Tribal to unlock their global potential.
days to go: Expired investment: £149,310
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph